Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2651 participants.

Also called NCT01442038

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,651 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01442038
  • EudraCT 2011-002507-15
Main results
  • Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial Lancet (London, England), 2016-01-09 DOI, PubMed 26474810
Other papers using this trial's data
  • Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial Circulation, 2016-01-05 DOI, PubMed 26555329
  • Relationship Between Optimism and Outcomes in Patients With Chronic Angina Pectoris The American journal of cardiology, 2019-05-01 DOI, PubMed 30771861, PMC7064151 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Belgium, Canada, Czechia, France, Germany, Israel, Italy, Netherlands, Poland, Russia, Spain, Sweden, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01442038. Randomized; triple masking; primary purpose treatment. Start 2011-10 (registry gives no type); primary completion 2015-02 (actual). Results posted on 2016-07-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
Acronym
RIVER-PCI
Condition
Angina Pectoris
Intervention (Drug)
Ranolazine
Intervention (Drug)
Placebo
Lead sponsor
Gilead Sciences (class: industry)

Record details

Record id
cardio:ct-nct01442038
Content hash
3fdd00734a2f8c78e3c1532aa77b184a7c6d58702a9c914c59717b6406cd437d